Lexicon Pharmaceuticals
LXRX • NASDAQ
Lexicon Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Michael S. Exton, with a market cap of $699.1M.
CEOMichael S. Exton
Next Earnings
Upcoming earnings announcement for Lexicon Pharmaceuticals
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.04
Revenue Estimate
$9.4M
Earnings History
Past 12 earnings reports for Lexicon Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 5, 2026 | Q4 2025 | -$0.04Est: -$0.07 | +42.9% | $5.5MEst: $3.7M | +50.4% |  10-K |
| Nov 6, 2025 | Q3 2025 | -$0.04Est: -$0.07 | +42.9% | $14.2MEst: $5.1M | +175.6% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $0.01Est: -$0.08 | +112.5% | $28.9MEst: $5.5M | +423.3% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.07Est: -$0.10 | +30.0% | $1.3MEst: $2.1M | -40.5% | 10-Q |
| Mar 6, 2025 | Q4 2024 | -$0.09Est: -$0.12 | +25.0% | $26.6MEst: $6.5M | +309.8% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.18Est: -$0.16 | -12.5% | $1.8MEst: $2.9M | -40.3% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.17Est: -$0.19 | +10.5% | $1.6MEst: $2.8M | -41.8% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.20Est: -$0.20 | 0.0% | $1.1MEst: $1.4M | -17.5% | 10-Q |
| Mar 11, 2024 | Q4 2023 | -$0.20Est: -$0.22 | +9.1% | $702.0KEst: $1.2M | -43.4% | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.21Est: -$0.21 | 0.0% | $162.0KEst: $2.1M | -92.1% | — |
| Aug 3, 2023 | Q2 2023 | -$0.22Est: -$0.17 | -29.4% | $317.0KEst: $70.0K | +352.9% | 10-Q |
| May 2, 2023 | Q1 2023 | -$0.17Est: -$0.18 | +5.6% | $24.0KEst: $30.0K | -20.0% | — |